术前系统免疫炎症指数对非小细胞肺癌患者预后价值的系统评价与Meta分析  

Prognostic value of the preoperative systemic immune-inflammation index in patients with non-small cell lung cancer:A systematic review and meta-analysis

作　　者：陈梦琪 刘珂萌 赵华琴[1] 贺霞[1] CHEN Mengqi;LIU Kemeng;ZHAO Huaqin;HE Xia(Department of Respiratory and Critical Care Medicine,Second People's Hospital of Deyang City,Deyang,618000,Sichuan,P.R.China;Department of Thoracic Surgery,Renshou County People's Hospital,Meishan,620500,Sichuan,P.R.China)

机构地区：[1]德阳市第二人民医院呼吸与危重症医学科,四川德阳618000 [2]仁寿县人民医院胸心外科,四川眉山620500

出　　处：《中国胸心血管外科临床杂志》2023年第3期440-446,共7页Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

摘　　要：目的探讨非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的术前系统免疫炎症指数(systemic immune-inflammation index,SII)与预后之间的关系。方法系统检索PubMed、Web of Science、EMbase、The Cochrane Library、万方和中国知网数据库以确定符合条件的研究。检索时限为建库至2021年12月。结合风险比(hazard ratio,HR)和95%置信区间(confidence interval,CI),评估术前SII与NSCLC患者的总生存期、无病生存期和无复发生存期的相关性。结果共纳入11篇文献,涉及9180例患者。Meta分析结果显示较高的SII与较差的总生存期[HR=1.61,95%CI(1.36,1.90),P<0.001]、无病生存期[HR=1.50,95%CI(1.34,1.68),P<0.001]和无复发生存期[HR=1.17,95%CI(1.04,1.33),P<0.001]显著相关。亚组分析也进一步验证了上述结果。结论术前SII是预测可手术的NSCLC患者预后的一个强有力的生物标志物,有助于预后评估和治疗策略的制定。然而,需要更多的前瞻性研究来验证。Objective To explore the association between the preoperative systemic immune-inflammation index(SII)and prognosis in non-small cell lung cancer(NSCLC)patients.Methods A comprehensive literature survey was performed on PubMed,Web of Science,EMbase,The Cochrane Library,Wanfang,and CNKI databases to search the related studies from inception to December 2021.The hazard ratio(HR)and 95%confidence interval(CI)were combined to evaluate the correlation of the preoperative SII with overall survival(OS),disease-free survival(DFS),and recurrencefree survival(RFS)in NSCLC patients.Results A total of 11 studies involving 9180 patients were eventually included.The combined analysis showed that high SII levels were significantly associated with worse OS(HR=1.61,95%CI 1.36-1.90,P<0.001),DFS(HR=1.50,95%CI 1.34-1.68,P<0.001),and RFS(HR=1.17,95%CI 1.04-1.33,P<0.001).Subgroup analyses also further verified the above results.Conclusion Preoperative SII is a powerful prognostic biomarker for predicting outcome in patients with operable NSCLC and contribute to prognosis evaluation and treatment strategy formulation.However,more well-designed and prospective studies are warranted to verify our findings.

关 键 词：系统免疫炎症指数 非小细胞肺癌 预后 系统评价/META分析 

分 类 号：R734.2[医药卫生—肿瘤]